Loading...

Garon Edward

TitleHealth Sciences Associate Clinical Professor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
Address2825 Santa Monica Blvd.
Suite 200 TORL
Admin Code 1559
Santa Monica CA 90404
Phone(310) 586-0841
vCardDownload vCard
    Other Positions
    TitleHealth Sciences Associate Clinical Professor


    Collapse Research 
    Collapse Research Activities and Funding
    A model for predicting response to PD-1 inhibitors in NSCLC
    NIH/NCI R01CA208403Jan 3, 2017 - Dec 31, 2021
    Role: Principal Investigator
    Inhibiting EGFR and ER pathways in NSCLC
    NIH/NCI K23CA149079Jul 15, 2011 - Jun 30, 2016
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018 Jul 17; 6(1):75. PMID: 30012210.
      View in: PubMed
    2. Williamson TJ, Choi AK, Kim JC, Garon EB, Shapiro JR, Irwin MR, Goldman JW, Bornyazan K, Carroll JM, Stanton AL. A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment. J Thorac Oncol. 2018 Jul 05. PMID: 29981926.
      View in: PubMed
    3. Lisberg A, Garon EB. The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. J Thorac Oncol. 2018 Aug; 13(8):1058-1059. PMID: 30056858.
      View in: PubMed
    4. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 Sep; 123:91-98. PMID: 30089602.
      View in: PubMed
    5. Turner D, Kondic AG, Anderson KM, Robinson A, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018 Jun 11. PMID: 29891725.
      View in: PubMed
    6. Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC. J Thorac Oncol. 2018 May 24. PMID: 29874546.
      View in: PubMed
    7. Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2018 May 02. PMID: 29721850.
      View in: PubMed
    8. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Apr 16. PMID: 29658856.
      View in: PubMed
    9. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, Tsao A, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon E. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 Jun; 120:62-69. PMID: 29748017.
      View in: PubMed
    10. Sandler KA, Abtin F, Suh R, Cook RR, Felix C, Lee JM, Garon EB, Wu J, Luterstein EM, Agazaryan N, Tenn SE, Lee C, Steinberg ML, Lee P. A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. Int J Radiat Oncol Biol Phys. 2018 Jul 01; 101(3):564-573. PMID: 29893274.
      View in: PubMed
    11. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol. 2018 May; 13(5):682-688. PMID: 29518553.
      View in: PubMed
    12. Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep. 2018 Feb 07; 8(1):2592. PMID: 29416054.
      View in: PubMed
    13. Ellis-Caleo T, Lisberg A, Tucker DA, Garon EB. High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. J Thorac Dis. 2018 Feb; 10(Suppl 3):S397-S403. PMID: 29593885.
      View in: PubMed
    14. Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res. 2018 Jan 30. PMID: 29382669.
      View in: PubMed
    15. Ramalingam SS, Pérol M, Reck M, Kowalyszyn RD, Gautschi O, Kimmich M, Cho EK, Czyzewicz G, Grigorescu A, Karaseva N, Dakhil S, Lee P, Zimmerman A, Sashegyi A, Alexandris E, Carter GC, Winfree KB, Garon EB. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Clin Lung Cancer. 2018 May; 19(3):270-279.e3. PMID: 29373274.
      View in: PubMed
    16. Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Apr; 13(4):576-584. PMID: 29247830.
      View in: PubMed
    17. Tsai EB, Pomykala K, Ruchalski K, Genshaft S, Abtin F, Gutierrez A, Kim HJ, Li A, Adame C, Jalalian A, Wolf B, Garon EB, Goldman JW, Suh R. Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. Radiology. 2018 04; 287(1):326-332. PMID: 29232184.
      View in: PubMed
    18. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 Mar 01; 24(5):1038-1047. PMID: 29217530.
      View in: PubMed
    19. Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018 02 02; 359(6375):582-587. PMID: 29217585.
      View in: PubMed
    20. Lisberg A, Garon EB. Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. Transl Lung Cancer Res. 2017 Dec; 6(Suppl 1):S39-S40. PMID: 29299407.
      View in: PubMed
    21. Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017 Dec 01; 28(12):2932-2942. PMID: 28950290.
      View in: PubMed
    22. Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 May; 19(3):213-220.e4. PMID: 29317191.
      View in: PubMed
    23. Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15; 123(24):4800-4807. PMID: 29125624.
      View in: PubMed
    24. Garcia-Gathright JI, Matiasz NJ, Adame C, Sarma KV, Sauer L, Smedley NF, Spiegel ML, Strunck J, Garon EB, Taira RK, Aberle DR, Bui AAT. Evaluating Casama: Contextualized semantic maps for summarization of lung cancer studies. Comput Biol Med. 2018 Jan 01; 92:55-63. PMID: 29149658.
      View in: PubMed
    25. Cummings AL, Garon EB. The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? Cancer Biol Med. 2017 Nov; 14(4):341-347. PMID: 29372100.
      View in: PubMed
    26. Garon EB. Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. N Engl J Med. 2017 06 22; 376(25):2483-2485. PMID: 28636845.
      View in: PubMed
    27. Gaut D, Sim MS, Yue Y, Wolf BR, Abarca PA, Carroll JM, Goldman JW, Garon EB. Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2018 Jan; 19(1):e19-e28. PMID: 28712979.
      View in: PubMed
    28. Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Carter GC, Alexandris E, Garon EB. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer. 2017 Oct; 112:126-133. PMID: 29191585.
      View in: PubMed
    29. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul; 18(7):895-903. PMID: 28551359.
      View in: PubMed
    30. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15; 23(16):4556-4568. PMID: 28468947.
      View in: PubMed
    31. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. PMID: 28411193.
      View in: PubMed
    32. Che J, Yu V, Garon EB, Goldman JW, Di Carlo D. Biophysical isolation and identification of circulating tumor cells. Lab Chip. 2017 04 11; 17(8):1452-1461. PMID: 28352869.
      View in: PubMed
    33. Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017 04 01; 28(4):874-881. PMID: 28168303.
      View in: PubMed
    34. Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, Nadanaciva S, O'Connell J, Sbar E, Cho BC. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 2017 04; 106:76-82. PMID: 28285698.
      View in: PubMed
    35. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep. 2017 01 17; 18(3):601-610. PMID: 28099841.
      View in: PubMed
    36. Garon EB, Neidhart JD, Gabrail NY, de Oliveira MR, Balkissoon J, Kabbinavar F. A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Onco Targets Ther. 2016; 9:7275-7283. PMID: 27942221.
      View in: PubMed
    37. Blumenschein G, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, Glaspy J, Berry DA, Korytowsky B, Zhu J, Lin WH, Bennett K, Reynolds C. PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S307. PMID: 27969526.
      View in: PubMed
    38. Dhar M, Pao E, Renier C, Go DE, Che J, Montoya R, Conrad R, Matsumoto M, Heirich K, Triboulet M, Rao J, Jeffrey SS, Garon EB, Goldman J, Rao NP, Kulkarni R, Sollier-Christen E, Di Carlo D. Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells. Sci Rep. 2016 10 14; 6:35474. PMID: 27739521.
      View in: PubMed
    39. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. J Thorac Oncol. 2016 Oct; 11(10S):S174-S175. PMID: 27676480.
      View in: PubMed
    40. Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C, Horn L, Patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB. P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy. J Thorac Oncol. 2016 Oct; 11(10S):S241-S242. PMID: 27676573.
      View in: PubMed
    41. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy. J Thorac Oncol. 2016 Oct; 11(10S):S242-S243. PMID: 27676575.
      View in: PubMed
    42. Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O'brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opin Biol Ther. 2016 12; 16(12):1479-1489. PMID: 27650132.
      View in: PubMed
    43. Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon EB. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016 09; 27(9):1712-8. PMID: 27287210.
      View in: PubMed
    44. Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):96-99. PMID: 27894601.
      View in: PubMed
    45. Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016 07; 27(7):1291-8. PMID: 27117531.
      View in: PubMed
    46. Garcia-Gathright JI, Matiasz NJ, Garon EB, Aberle DR, Taira RK, Bui AAT. Toward patient-tailored summarization of lung cancer literature. IEEE EMBS Int Conf Biomed Health Inform. 2016 Feb; 2016:449-452. PMID: 28721401.
      View in: PubMed
    47. Lisberg A, Garon EB. The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 Mar 17. PMID: 26986923.
      View in: PubMed
    48. Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, Garon EB, Goldman J, Rao J, Sledge GW, Pegram MD, Sheth S, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D. Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. Oncotarget. 2016 Mar 15; 7(11):12748-60. PMID: 26863573; PMCID: PMC4914319.
    49. Garon EB. The race for combined checkpoint inhibition in NSCLC. Lancet Oncol. 2016 Mar; 17(3):259-60. PMID: 26858123.
      View in: PubMed
    50. Pérol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer. 2016 Mar; 93:95-103. PMID: 26898621.
      View in: PubMed
    51. Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 01; 122(5):766-72. PMID: 26695526; PMCID: PMC5038591 [Available on 03/01/17].
    52. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 09; 387(10027):1540-50. PMID: 26712084.
      View in: PubMed
    53. Dhar M, Wong J, Karimi A, Che J, Renier C, Matsumoto M, Triboulet M, Garon EB, Goldman JW, Rettig MB, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D. High efficiency vortex trapping of circulating tumor cells. Biomicrofluidics. 2015 Nov; 9(6):064116. PMID: 26697126; PMCID: PMC4684572 [Available on 12/17/16].
    54. Garon EB. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Semin Oncol. 2015 Oct; 42 Suppl 2:S11-8. PMID: 26477470.
      View in: PubMed
    55. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015 Nov; 51(16):2321-9. PMID: 26283035.
      View in: PubMed
    56. McNamara M, Arnold C, Sarma K, Aberle D, Garon E, Bui AA. Patient Portal Preferences: Perspectives on Imaging Information. J Assoc Inf Sci Technol. 2015 Aug 01; 66(8):1606-1615. PMID: 26191535.
      View in: PubMed
    57. Garon EB. Selecting patients for immune checkpoint inhibition in lung cancer. Clin Adv Hematol Oncol. 2015 Aug; 13(8):490-2. PMID: 26351808.
      View in: PubMed
    58. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9. PMID: 25923550.
      View in: PubMed
    59. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21; 372(21):2018-28. PMID: 25891174.
      View in: PubMed
    60. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 03; 348(6230):124-8. PMID: 25765070; PMCID: PMC4993154.
    61. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9. PMID: 25611228.
      View in: PubMed
    62. Garcia-Gathright JI, Oh A, Abarca PA, Han M, Sago W, Spiegel ML, Wolf B, Garon EB, Bui AA, Aberle DR. Representing and extracting lung cancer study metadata: study objective and study design. Comput Biol Med. 2015 Mar; 58:63-72. PMID: 25618216; PMCID: PMC4331232.
    63. Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015 Feb; 20(2):224-6. PMID: 25568147; PMCID: PMC4319629.
    64. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693; PMCID: PMC4346098.
    65. Garon EB, Abarca PA, Strunck JL, Nameth D, Neumann C, Wolf B, Kim KY, Marx C, Elashoff RM. Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. Crit Rev Oncog. 2015; 20(5-6):339-47. PMID: 27279233.
      View in: PubMed
    66. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90. PMID: 27279236.
      View in: PubMed
    67. Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8. PMID: 25516338.
      View in: PubMed
    68. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23; 384(9944):665-73. PMID: 24933332.
      View in: PubMed
    69. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006. PMID: 24846037; PMCID: PMC4163053.
    70. Rwigema JC, Chen AM, Wang PC, Lee JM, Garon E, Lee P. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy. Clin Lung Cancer. 2014 Jul; 15(4):287-93. PMID: 24594401.
      View in: PubMed
    71. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res. 2014 May; 12(5):765-74. PMID: 24469837; PMCID: PMC4020971.
    72. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014 Mar; 140(3):443-52. PMID: 24442098; PMCID: PMC3939783.
    73. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57. PMID: 24145346; PMCID: PMC4881367.
    74. Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju C. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol. 2013 Oct; 8(10):1308-16. PMID: 23981966; PMCID: PMC4715866.
    75. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res. 2013; 5(5):481-96. PMID: 23977408; PMCID: PMC3745436.
    76. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91. PMID: 23515407; PMCID: PMC3643999.
    77. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun; 12(6):890-900. PMID: 23493311; PMCID: PMC3681857.
    78. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8. PMID: 23399957; PMCID: PMC3573351.
    79. Goldman JW, Garon EB. Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S377-8. PMID: 23160324; PMCID: PMC3741037.
    80. Kazmi N, Márquez-Garbán DC, Aivazyan L, Hamilton N, Garon EB, Goodglick L, Pietras RJ. The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag. 2012 Dec; 1(4):259-272. PMID: 23650476.
      View in: PubMed
    81. Chou T, Finn RS, Garon EB. Expanding options for EGFR targeting in lung cancer. Transl Lung Cancer Res. 2012 Dec; 1(4):287-8. PMID: 25806196; PMCID: PMC4367554.
    82. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21. PMID: 22982661.
      View in: PubMed
    83. Kurita K, Garon EB, Stanton AL, Meyerowitz BE. Uncertainty and psychological adjustment in patients with lung cancer. Psychooncology. 2013 Jun; 22(6):1396-401. PMID: 22887017; PMCID: PMC4036804.
    84. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol M. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer. 2012 Nov; 13(6):505-9. PMID: 22853980.
      View in: PubMed
    85. Garon EB. Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer. 2012 Sep; 77(3):475-81. PMID: 22795702; PMCID: PMC3737740.
    86. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-42. PMID: 22700995.
      View in: PubMed
    87. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, Chia D, Elashoff D, Park NH, Wong DTW. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci. 2012 Oct; 69(19):3341-3350. PMID: 22689099; PMCID: PMC4121486.
    88. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9. PMID: 22496272; PMCID: PMC3715059.
    89. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics. 2012 Feb; 11(2):M111.012112. PMID: 22096114; PMCID: PMC3277759.
    90. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. PMID: 22045706; PMCID: PMC5021512.
    91. Garon EB, Dubinett SM. Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1791-2. PMID: 22005532; PMCID: PMC3812544.
    92. Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B, Reber HA. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011 Jul; 146(7):836-43. PMID: 21768431.
      View in: PubMed
    93. Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, Horvath S, Chia D, Garon E, Goodglick L, Pietras RJ. Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids. 2011 Aug; 76(9):910-20. PMID: 21600232; PMCID: PMC3129425.
    94. Greaves SM, Brown K, Garon EB, Garon BL. The new staging system for lung cancer: imaging and clinical implications. J Thorac Imaging. 2011 May; 26(2):119-31. PMID: 21508734.
      View in: PubMed
    95. Mong C, Garon EB, Fuller C, Mahtabifard A, Mirocha J, Mosenifar Z, McKenna R. High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation. J Cardiothorac Surg. 2011 Feb 25; 6:19. PMID: 21352550; PMCID: PMC3056729.
    96. Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011 Mar 01; 17(5):1131-9. PMID: 21220471; PMCID: PMC3048920.
    97. Hosmer WD, Dubinett SM, Garon EB. Novel drugs--miscellaneous category. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S468-9. PMID: 21102242.
      View in: PubMed
    98. Ujhazy P, Garon EB. Proapoptotic agents in lung cancer. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S480-1. PMID: 21102248.
      View in: PubMed
    99. Garon EB, Dubinett SM. Poly(ADP-ribose) polymerase inhibitors. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S455-6. PMID: 21102236.
      View in: PubMed
    100. Pollock J, Garon EB. Management of small-cell lung cancer: time to move forward. Oncology (Williston Park). 2010 Oct; 24(11):1043, 1046-7. PMID: 21155456.
      View in: PubMed
    101. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010 Jul; 9(7):1985-94. PMID: 20587667; PMCID: PMC2939826.
    102. Garon EB, Dubinett SM. Intracellular signaling molecules. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1057-8. PMID: 19861915.
      View in: PubMed
    103. Lee JM, Garon E, Wong DT. Salivary diagnostics. Orthod Craniofac Res. 2009 Aug; 12(3):206-11. PMID: 19627522; PMCID: PMC2909324.
    104. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008 Feb; 3(2):107-10. PMID: 18303428.
      View in: PubMed
    105. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1405-21. PMID: 17944566.
      View in: PubMed
    106. Garon EB, Sawcer D, Vernier PT, Tang T, Sun Y, Marcu L, Gundersen MA, Koeffler HP. In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer. 2007 Aug 01; 121(3):675-82. PMID: 17417774.
      View in: PubMed
    107. Garon EB, Marcu L, Luong Q, Tcherniantchouk O, Crooks GM, Koeffler HP. Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells. Leuk Res. 2007 May; 31(5):643-51. PMID: 17027955.
      View in: PubMed
    108. Vernier PT, Sun Y, Wang J, Thu MM, Garon E, Valderrabano M, Marcu L, Koeffler HP, Gundersen MA. Nanoelectropulse intracellular perturbation and electropermeabilization technology: phospholipid translocation, calcium bursts, chromatin rearrangement, cardiomyocyte activation, and tumor cell sensitivity. Conf Proc IEEE Eng Med Biol Soc. 2005; 6:5850-3. PMID: 17281590.
      View in: PubMed